BPG is committed to discovery and dissemination of knowledge
Cited by in CrossRef
For: Shen K, Singh AD, Modaresi Esfeh J, Wakim-Fleming J. Therapies for non-alcoholic fatty liver disease: A 2022 update. World J Hepatol 2022; 14(9): 1718-1729 [PMID: 36185717 DOI: 10.4254/wjh.v14.i9.1718]
URL: https://www.wjgnet.com/1948-5182/full/v14/i9/1718.htm
Number Citing Articles
1
Femmy Nurul Akbar, Safira Rosiana Choirida, Ahmad Zaqi Muttaqin, Fika Ekayanti, Hoirun Nisa, Hari Hendarto. Telemedicine as an Option for Monitoring Metabolic Dysfunction-Associated Fatty Liver Disease (MAFLD) Patients Facing the COVID-19 Pandemic: A Systematic Review and Meta-AnalysisJournal of Personalized Medicine 2024; 14(3): 281 doi: 10.3390/jpm14030281
2
Sima Jafarirad, Reza Goodarzi, Narges Mohammadtaghvaei, Maryam Dastoorpoor, Pejman Alavinejad. Effectiveness of the pomegranate extract in improving hepatokines and serum biomarkers of non-alcoholic fatty liver disease: A randomized double blind clinical trialDiabetes & Metabolic Syndrome: Clinical Research & Reviews 2023; 17(1): 102693 doi: 10.1016/j.dsx.2022.102693
3
Changzhen Fu, Meng-Lin Xiang, Shaolang Chen, Geng Dong, Zibo Liu, Chong-Bo Chen, Jiajian Liang, Yingjie Cao, Mingzhi Zhang, Qingping Liu. Molecular Drug Simulation and Experimental Validation of the CD36 Receptor Competitively Binding to Long-Chain Fatty Acids by 7-Ketocholesteryl-9-carboxynonanoateACS Omega 2023; 8(31): 28277 doi: 10.1021/acsomega.3c02082
4
Yuval Ishay, Joel Neutel, Yotam Kolben, Ram Gelman, Orly Sneh Arbib, Oliver Lopez, Helena Katchman, Rizwana Mohseni, Miriam Kidron, Yaron Ilan. Oral Insulin Alleviates Liver Fibrosis and Reduces Liver Steatosis in Patients With Metabolic Dysfunction-associated Steatohepatitis and Type 2 Diabetes: Results of Phase II Randomized, Placebo-controlled Feasibility Clinical TrialGastro Hep Advances 2024; 3(3): 417 doi: 10.1016/j.gastha.2023.11.016
5
Yu-long Hu, Qiaoli Ma, Xiaoqiang Dong, Yuanfang Kong, Juntao Cai, Jieming Li, Chunhong Dong. Research progress on the therapeutic effects of polysaccharides on non-alcoholic fatty liver diseasesFrontiers in Nutrition 2023; 10 doi: 10.3389/fnut.2023.1107551